Actively Recruiting

Phase Not Applicable
Age: 50Years +
All Genders
NCT06046118

Photobiomodulation in Dry Age Related Macular Degeneration

Led by Azienda Ospedaliera Universitaria Mater Domini, Catanzaro · Updated on 2024-09-19

180

Participants Needed

7

Research Sites

91 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to evaluate effects of consecutive Yellow and Red Light Emitting Diode photobiomodulation in dry age-related macular degeneration (AMD). The main questions it aims to answer are: * Is Yellow and Red Light Emitting Diode photobiomodulation effective in decreasing drusen volume in patients affected by dry AMD? * Does Yellow and Red Light Emitting Diode photobiomodulation increase visual acuity and contrast sensitivity in patients affected by dry AMD? Participants will be randomly assigned to a treatment or a sham group. Treatment consists in two cycles with two phases each: * 1st phase: 300 seconds of continuous Yellow light with eyes closed + 60 seconds of pulsed Yellow light with eyes opened; * 2d phase: 300 seconds of continuous Red light with eyes closed + 60 seconds of pulsed Red light with eyes opened. Cycle 1 consists of 8 sessions (two PBM per week for 4 weeks) and cycle 2 consists of 6 sessions (two PBM per week for 3 weeks). Researchers will compare patients in the treatment group to those in the sham group to evaluate differences in objective signs and subjective symptoms of dry AMD.

CONDITIONS

Official Title

Photobiomodulation in Dry Age Related Macular Degeneration

Who Can Participate

Age: 50Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Best corrected visual acuity (BCVA) on ETDRS chart greater than 40 letters at 4 meters
  • Diagnosis of dry age-related macular degeneration (AMD) with AREDS grade 2 or 3
  • Ability to communicate well with the investigator and understand and follow study requirements
Not Eligible

You will not qualify if you...

  • History of epilepsy
  • Presence of neurological diseases
  • Presence of psychiatric pathologies
  • Herpes virus infections
  • Dense cataract
  • Pregnancy
  • Other significant ocular and/or retinal diseases

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

University of Paris

Paris, France

Actively Recruiting

2

Università degli Studi di Ferrara

Ferrara, Italy

Actively Recruiting

3

Università degli studi della Campania Luigi Vanvitelli

Naples, Italy

Actively Recruiting

4

Università di Torino

Torino, Italy

Actively Recruiting

5

University of Ankara

Ankara, Turkey (Türkiye)

Actively Recruiting

6

Koç University Hospital

Koç, Turkey (Türkiye)

Actively Recruiting

7

Earlam and Christopher

Taunton, United Kingdom

Actively Recruiting

Loading map...

Research Team

G

Giuseppe Giannaccare

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here